Risk management of renal biopsy: 1387 cases over 30 years in a single centre.

摘要: Background  Although renal biopsy is largely employed, even in old patients with systemic diseases, few clinical studies have addressed its risk management. We aimed to obtain a comprehensive assessment of safety/utility ratio percutaneous biopsy. Patients and methods  Retrospective review all the 1387 who consecutively underwent single centre over three decades (1973–2002) was made, calculation complications, multivariate logistical analyses evaluate factors rate alteration hypotheses by pathological diagnosis. Results  There were no deaths five major (0·36%). One nephrectomy (0·07%), two surgical revisions (0·1%) arterial-venous fistulae (0·1%). also 337 minor bleeding complications (24·2%) (16·4% gross haematuria 7·8% clinically relevant haematomas needing at least prolonged bed rest). Multivariate demonstrated that for significantly increased autoimmune diseases odds (OR) 2·06, 95% confidence interval (CI) = 1·40–3·01, end-stage kidney/acute-tubular necrosis (OR 2·96, CI = 1·19–7·30), time test (BTT) 1·87, CI = 1·17–2·83). Among 1288 cases which hypothesis before recorded, pathology changed previous diagnoses 423/1,288 (32·8%) cases. Conclusions  Risk demonstrates useful procedure low incidence serious complications. Platelet function only modifiable factor related suggesting need more standardized alternative BTT. should be evaluated select low-risk as ‘a day case procedure’, order build adequate management strategies.